Although there was no association of baseline SMYD3 protein levels with overall (OS) and progression-free survival (PFS) in the University of Chicago dataset and the HPV-negative HNSCC cohort of the CPTAC, there was a trend towards worse survival in patients with higher SMYD3 mRNA levels in the larger HPV-negative HNSCC cohort of the TCGA (OS, log-rank p = 0.08, HR = 0.71; PFS, log-rank p = 0.07, HR = 0.74) (Fig. 5E, Supplementary Fig. 10). Here, SMYD3 is linked to head and neck squamous cell carcinoma.